January 2026 in “Biomolecules” TSC22D genes are key in metabolic diseases and cancer, offering potential as treatment targets.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
January 2017 in “Enlighten: Publications (The University of Glasgow)” Activating β-catenin and inactivating PTEN cause follicular tumors, not papillomas, similar to those in Cowden’s Disease.
February 2014 in “Cancer Research” Recent findings advanced understanding of cancer mechanisms and potential treatments.
January 2013 in “eScholarship (California Digital Library)” Activating Wnt signaling improves the efficiency and safety of creating stem cells.
January 2009 in “Bradford Scholars (University of Bradford)” BMP signaling helps prevent skin tumors by blocking cancer-promoting pathways.
50 citations
,
February 2007 in “The Journal of Pathology” Somatic BHD mutations are rare in Japanese renal tumors.
39 citations
,
February 2011 in “American Journal of Dermatopathology” Onychomatricoma is a unique nail tumor that mimics the entire nail unit and is not related to other hair-related tumors.
2 citations
,
May 2021 in “Bioengineering” Blood stem cells are diverse, influenced by many factors, and understanding them is key for progress in regenerative medicine.
August 2025 in “Processes” Rosemary may help reduce dyspepsia and gastric cancer risk.
December 2014 in “TDX (Tesis Doctorals en Xarxa)” Cellular senescence is crucial for normal embryonic development but contributes to aging in adults.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
Onychomatricoma is a unique nail tumor, not related to other hair-related tumors.
August 1986 in “Journal of The American Academy of Dermatology” Minoxidil showed a 30% success rate for hair growth in a study, and various skin treatments were effective, but some had limitations or side effects.
June 2011 in “Expert Review of Dermatology” Researchers discovered potential origins and new treatments for skin cancer, including biomarkers for melanoma and therapies that reduce tumor growth.
April 2018 in “Journal of Investigative Dermatology” The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
April 2023 in “Journal of Investigative Dermatology” Mutations in the SHH pathway in certain skin cells can cause skin tumors and abnormal hair growth.
64 citations
,
February 2008 in “Cancer Research” Inactivating both p53 and Rb genes in mice speeds up aggressive skin cancer development.
Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.
June 2008 in “The Knowledge Bank (The Ohio State University)” Smad2 and Smad3 are essential for normal skin development, and their absence causes severe skin issues and cancer.
October 2024 in “Frontiers in Oncology” A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.
May 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Loss of TET2 increases the risk of skin and oral cancer.
2 citations
,
June 2023 in “Journal of cell science” Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
ETS2 is crucial in squamous cell carcinoma development and could be a therapeutic target.
1 citations
,
April 2022 in “Cell Death Discovery” Increasing Smurf2 hinders hair follicle stem cell differentiation and wound healing.
ETS2 drives cancer progression in squamous cell carcinoma and is linked to poor patient outcomes.
52 citations
,
September 2012 in “Oncogene” 60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.